Biotech | June 01, 2022
Novavax initiates phase 3 trial of its COVID-19 omicron booster
Trial will assess safety and antibody responses of NVX-CoV2515 to the Omicron variant of COVID-19
Trial will assess safety and antibody responses of NVX-CoV2515 to the Omicron variant of COVID-19
The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis
Pharmaceutical manufacturer uses Veeam solutions to accelerate mission-critical backups by 95% and restore data in minutes, not hours
OS-SiA is the industry’s first AI-enabled digital scanner that will provide real-time predictive analysis and actionable insights
Dr Jitendra Singh said, the Biotech Park would act as a hub for incubation of new ideas
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Motrin Oral Suspension, 100 mg/5 mL, of McNeil Consumer Healthcare (McNeil)
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
Already an existing partner and supplier of ingredients to Medisca, striking this agreement with SUANFARMA involved reinforcing a well-established symbiotic relationship between two companies committed to world-class quality, service, and price
The company’s annual sales grew from Rs 548.12 crore in FY 2020-21 to Rs 598.65 crore this fiscal
68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
